15-year experience with rotavirus vaccination in Mexico: a systematic literature review

ABSTRACT

A systematic review was conducted in Mexico to consolidate and evaluate evidence after 15 years of rotavirus vaccination, according to the National Immunization Program. Five databases were screened to identify published articles (January 2000–February 2020) with evidence on all clinical and epidemiological endpoints (e.g. immunogenicity, safety, efficacy, impact/effectiveness) of rotavirus vaccination in Mexico. Twenty-two articles were identified (observational studies including health-economic models: 17; randomized controlled trials: 5). Fourteen studies evaluated a human attenuated vaccine (HRV), four studies evaluated both vaccines, and only two evaluated a bovine-human reassortant vaccine, with local efficacy data only for HRV. Local evidence shows vaccines are safe, immunogenic, efficacious, and provide an acceptable risk-benefit profile. The benefits of both vaccines in alleviating the burden of all-cause diarrhea mortality and morbidity are documented in several local post-licensure studies. Findings signify overall benefits of rotavirus vaccination and support the continued use of rotavirus vaccine in Mexico.

KEYWORDS:

• acute diarrhea
• rotavirus gastroenteritis
• Mexico
• rotavirus vaccine
• systematic review
• immunogenicity
• health economics
• disease burden
• intussusception

Acknowledgments

The authors would also like to thank the Business & Decision Life Sciences platform for editorial assistance and manuscript coordination, on behalf of GSK. Maxime Bessières coordinated manuscript development and editorial support and Amrita Ostawal (Arete Communication UG) provided writing support for this literature review.

Disclosure of potential conflicts of interest

AGH, EO, MYCA, DC, and RC are employed by the GSK group of companies. MYCA, EO, and RC hold shares in the GSK group of companies. AAF is an external GSK employee hired by Randstad. All authors declare no non-financial relationships and activities.

Trademark

Rotarix is a trademark owned by or licensed to the GSK group of companies.

RotaTeq is a trademark of Merck Sharp & Dohme Corp.

ROTAVAC is a trademark of Bharat Biotech International Limited.

RotaSIIL is a trademark of the Serum Institute of India.

Contributorship

All authors comply with the ICMJE criteria for authorship. All authors were involved in the conception and/or the design of the study. AGH conducted the study and the review analysis; both AGH and AAF participated in the data collection/generation of the study data. All authors were involved in the interpretation of the data. All authors reviewed and approved the final manuscript.

Supplementary material

Supplemental data for this article can be accessed on the publisher’s website at https://doi.org/10.1080/21645515.2021.1936859.

Additional information

Funding

GlaxoSmithKline Biologicals SA funded this study [HO-19-20101] and took in charge all costs associated with the development and publication of this manuscript.